{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:18:10Z","timestamp":1777936690802,"version":"3.51.4"},"reference-count":115,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100013365","name":"west china hospital, sichuan university","doi-asserted-by":"publisher","award":["RHM24101"],"award-info":[{"award-number":["RHM24101"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic DiseasesNational Science and Technology Major Project","award":["2023ZD0506100"],"award-info":[{"award-number":["2023ZD0506100"]}]},{"name":"Noncommunicable Chronic DiseasesNational Science and Technology Major Project","award":["2023ZD050610X"],"award-info":[{"award-number":["2023ZD050610X"]}]},{"name":"State Key Laboratory of Respiratory Health and Multimorbidity, State Key Laboratory Special Fund","award":["2060204"],"award-info":[{"award-number":["2060204"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["SCU2024D017"],"award-info":[{"award-number":["SCU2024D017"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated efficacy across multiple treatment lines for patients with EGFR-mutated non-small cell lung cancer (NSCLC). However, the optimal treatment sequence and comparative effectiveness vs alternative therapies remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A systematic review and meta-analysis was conducted following the PRISMA 2020 guidelines. Embase, Medline (via Ovid), PubMed, Cochrane Central Register of Controlled Trials, Web of Science, and Google Scholar were searched from inception to May 31, 2025. Clinical trials comparing osimertinib with other treatments (placebo, EGFR-tyrosine kinase inhibitors [TKIs], chemotherapy, targeted therapy) in patients with EGFR-mutated NSCLC were included. Primary outcomes included objective response rate (ORR), median progression-free survival (mPFS), disease control rate (DCR), overall survival (OS), and adverse events. Subgroup analyses were performed by treatment line and comparator type. Risk of bias was assessed using the Cochrane RoB 2 tool. Statistical analysis was performed using R version 4.5.0 with random-effects models for high heterogeneity (I\n                      <jats:sup>2<\/jats:sup>\n                      &gt;\u200950%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Sixteen studies encompassing 4931 patients were included. Osimertinib demonstrated significantly superior ORR compared to control treatments (relative risk [RR]\u2009=\u20091.59, 95% confidence interval [CI] = 1.16 to 2.17,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001), exceeding the minimal clinically important difference threshold. The mPFS benefit was substantial (standardized mean difference [SMD]\u2009=\u20094.53\u2009months, 95% CI = 1.23 to 7.82,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.0001), with greater improvements observed in first-line therapy (SMD\u2009=\u20093.25, 95% CI = 0.52 to 5.97) vs second-line treatment (SMD\u2009=\u20097.61, 95% CI = \u221210.08 to 25.30). The DCR was significantly improved (RR\u2009=\u20091.26, 95% CI = 1.05 to 1.52,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.0001). The OS showed modest but consistent improvement (SMD\u2009=\u20090.18, 95% CI = 0.11 to 0.26,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.0001) with no heterogeneity (I\n                      <jats:sup>2<\/jats:sup>\n                      =\u20090%). Osimertinib was most effective vs chemotherapy and showed consistent benefits vs first-generation TKIs. Adverse events included increased upper respiratory tract infections, skin toxicities, and QT prolongation, while nausea and alopecia were reduced.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Osimertinib demonstrates superior efficacy across multiple endpoints in patients with EGFR-mutated NSCLC, with benefits observed in both first-line and second-line settings. The treatment provides clinically meaningful benefits with a manageable safety profile, supporting its use as a preferred therapeutic option across different treatment sequences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795549261434260","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:26:38Z","timestamp":1774596398000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Osimertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Current Evidence"],"prefix":"10.1177","volume":"20","author":[{"given":"Xiumei","family":"Tang","sequence":"first","affiliation":[{"name":"Institute of Hospital Management, West China Hospital, Sichuan University, Chengdu, P.R. China"},{"name":"Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, P.R. China"},{"name":"Institute of Respiratory Health, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Chen","sequence":"additional","affiliation":[{"name":"Health Management Center, West China Tianfu Hospital, Sichuan University, Chengdu, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Health, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-4862","authenticated-orcid":false,"given":"Wenzhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Hospital Management, West China Hospital, Sichuan University, Chengdu, P.R. China"},{"name":"Department of Orthopedics, Qilu Hospital, Shandong University, Jinan, P.R. China"},{"name":"Department of Orthopedic Surgery, West China Hospital, Sichuan University, Chengdu, P.R. China"},{"name":"Centre for Orthopaedics, Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhoufeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Health, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904554"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.07.009"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-022-0951-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115262"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-01022-7"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02043-2"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00839-w"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2022.2132116"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1617"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13623"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.833773"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30508-3"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.10.006"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.459"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.039"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13738"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.09.023"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00931"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14120"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3325"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy179"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1126"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1690"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00806-5"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.07.004"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91657-7"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1973092"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4084"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00457"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32749"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.017"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00943-0"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.03.009"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.387"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0003"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.03.017"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31891"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1042"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.3223"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx017"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411817"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9363"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.05.003"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2100"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0425"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.2293"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1177\/17407745221093935"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx820"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.001"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.08.018"},{"key":"e_1_3_3_59_2","first-page":"1697","article-title":"The clinical efficacy of osimertinib combined with bevacizumab in the first-line treatment of advanced non-small cell lung cancer with EGFR sensitive mutations","volume":"21","author":"Wang X","year":"2022","unstructured":"Wang X, et al. The clinical efficacy of osimertinib combined with bevacizumab in the first-line treatment of advanced non-small cell lung cancer with EGFR sensitive mutations. J Clin Exp Med. 2022;21:1697-1700.","journal-title":"J Clin Exp Med"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.010"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01145-7"},{"key":"e_1_3_3_62_2","first-page":"28","article-title":"Efficacy of radiochemotherapy combined with osimertinib for the treatment of advanced non-small cell lung cancer","author":"Tian Huijuan YD","year":"2021","unstructured":"Tian Huijuan YD. Efficacy of radiochemotherapy combined with osimertinib for the treatment of advanced non-small cell lung cancer. Chin J Clin Oncol Rehabil. 2021;28.","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"e_1_3_3_63_2","first-page":"1927","article-title":"Curative effect of osimertinib combined with DP regimen in the treatment of advanced non-small cell lung cancer and its effect on serum hCAP18 and Pokemon","volume":"44","author":"Zhenyang C","year":"2021","unstructured":"Zhenyang C, Xin L, Yufeng J, Donghui X, Li T. Curative effect of osimertinib combined with DP regimen in the treatment of advanced non-small cell lung cancer and its effect on serum hCAP18 and Pokemon. Drug Eval Res. 2021;44: 1927-1933.","journal-title":"Drug Eval Res"},{"key":"e_1_3_3_64_2","article-title":"Clinical efficacy and safety of osimertinib combined with radiochemotherapy for advanced non-small cell lung cancer","volume":"27","author":"Wu H","year":"2020","unstructured":"Wu H, Ping L. Clinical efficacy and safety of osimertinib combined with radiochemotherapy for advanced non-small cell lung cancer. Chin J Clin Oncol Rehabil. 2020;27: 400-403.","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"e_1_3_3_65_2","article-title":"Efficacy and prognosis of osimertinib in advanced non-small cell lung cancer with positive T790M mutation","volume":"17","author":"Liu D","year":"2019","unstructured":"Liu D, Yahen X, Guoqin C, Xiaodan H, Xin L, Pengyuan W. Efficacy and prognosis of osimertinib in advanced non-small cell lung cancer with positive T790M mutation. Oncol Prog. 2019;17:2952-2955.","journal-title":"Oncol Prog"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.02.019"},{"key":"e_1_3_3_67_2","article-title":"Effect of osimertinib on T790M-positive advanced lung adenocarcinoma","volume":"33","author":"Lixiang Y Hongmei S","year":"2019","unstructured":"Lixiang Y Hongmei S, Yuan L, Wenzhang C. Effect of osimertinib on T790M-positive advanced lung adenocarcinoma. J Chin Pract Diagn Ther. 2019;33:395-397.","journal-title":"J Chin Pract Diagn Ther"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100271"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6758"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.04.012"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.05.006"},{"key":"e_1_3_3_72_2","first-page":"1305","article-title":"Clinical effect of bevacizumab combined with ositinibin in the treatment of advanced non-small cell lung cancer patients with EGFR-T790M mutation","volume":"31","author":"Su D","year":"2022","unstructured":"Su D, Zheng X, Han Y, et al. Clinical effect of bevacizumab combined with ositinibin in the treatment of advanced non-small cell lung cancer patients with EGFR-T790M mutation. Henan Med Res. 2022;31:1305-1309.","journal-title":"Henan Med Res"},{"key":"e_1_3_3_73_2","first-page":"843","article-title":"Efficacy of osimertinib combined with bevacizumab in advanced non-small cell lung cancer patients with acquired EGFR T790M mutation","volume":"25","author":"Gu Y","year":"2022","unstructured":"Gu Y, et al. Efficacy of osimertinib combined with bevacizumab in advanced non-small cell lung cancer patients with acquired EGFR T790M mutation. Zhongguo Fei Ai Za Zhi. 2022;25:843-851.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"e_1_3_3_74_2","first-page":"107","article-title":"Clinical study of ohitinib combined with bevacizumab in treatment of advanced lung cancer","volume":"36","author":"Chen S.","year":"2023","unstructured":"Chen S. Clinical study of ohitinib combined with bevacizumab in treatment of advanced lung cancer. Heilongjiang Med J. 2023;36:107-110.","journal-title":"Heilongjiang Med J"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.013"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.09.004"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00794-6"},{"key":"e_1_3_3_78_2","first-page":"273","article-title":"Study on the efficacy of osimertinib in the treatment of advanced lung adenocarcinoma with sensitive mutation of EGFR gene and analysis of the factors affecting brain metastasis","volume":"49","author":"Zhang Jing TZ","year":"2021","unstructured":"Zhang Jing TZ, Ding Yanan Zhao Xiaofei. Study on the efficacy of osimertinib in the treatment of advanced lung adenocarcinoma with sensitive mutation of EGFR gene and analysis of the factors affecting brain metastasis. Mod Med J. 2021;49:273-279.","journal-title":"Mod Med J"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-1357"},{"key":"e_1_3_3_80_2","article-title":"The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: a PRISMA-compliant systematic review and meta-analysis","volume":"99","author":"Liu J","year":"2020","unstructured":"Liu J, et al. The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: a PRISMA-compliant systematic review and meta-analysis. Medicine. 2020;99:e21826.","journal-title":"Medicine"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2165"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010247"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.04.004"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.69854\/jcq.2024.0016"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0009-8"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-025-02733-9"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13378"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107522"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx359"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32097"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.05.001"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00556-4"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0611-3"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108417"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108783"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa197"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510308"},{"key":"e_1_3_3_104_2","article-title":"Recent advances and future directions in sonodynamic therapy for cancer treatment","volume":"2024","author":"Datta P","year":"2024","unstructured":"Datta P, Moolayadukkam S, Chowdhury D, et al. Recent advances and future directions in sonodynamic therapy for cancer treatment. BME Front. 2024;2024:0080.","journal-title":"BME Front"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030459"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107189"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.20517\/jtgg.2023.55"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.01.008"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.20517\/jtgg.2023.47"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.34133\/bmef.0047"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.20517\/jtgg.2024.94"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.34133\/bmef.0062"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1002\/VIW.20250108"},{"key":"e_1_3_3_114_2","first-page":"185","article-title":"Harnessing the immune system and developing targeted vaccines: overall strategies of leveraging the body\u2019s natural defense mechanisms to enhance cancer treatment","volume":"2","author":"Banday AH.","year":"2025","unstructured":"Banday AH. Harnessing the immune system and developing targeted vaccines: overall strategies of leveraging the body\u2019s natural defense mechanisms to enhance cancer treatment. Regener Med Rep. 2025;2:185-192.","journal-title":"Regener Med Rep"},{"key":"e_1_3_3_115_2","first-page":"31","article-title":"Smart biomanufacturing for health equity in regenerative medicine therapies","volume":"2","author":"Henn AD","year":"2025","unstructured":"Henn AD, et al. Smart biomanufacturing for health equity in regenerative medicine therapies. Regener Med Rep. 2025; 2:31-35.","journal-title":"Regener Med Rep"},{"key":"e_1_3_3_116_2","article-title":"Drug pair-derived synergistic therapy of flavonoids luteolin and astragaloside IV promote neural repair following spinal cord injury via antioxidant and neuroprotective effect","volume":"9","author":"Lin W","year":"2025","unstructured":"Lin W, et al. Drug pair-derived synergistic therapy of flavonoids luteolin and astragaloside IV promote neural repair following spinal cord injury via antioxidant and neuroprotective effect. Precis Clin Med. 2025;9:pbaf037.","journal-title":"Precis Clin Med"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549261434260","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795549261434260","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549261434260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:40:41Z","timestamp":1777693241000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795549261434260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":115,"alternative-id":["10.1177\/11795549261434260"],"URL":"https:\/\/doi.org\/10.1177\/11795549261434260","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"11795549261434260"}}